Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

Frequency of Selected Single Nucleotide Polymorphisms in Phase With the Mutant and Wild-Type HTT Alleles in Huntington Disease Gene Expansion Carriers

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.

Who May Be Eligible (Plain English)

Who May Qualify: - Have signed the willing to sign a consent form Form (ICF) - Aged 25 to 60 years, inclusive, at the time of signing the ICF - Confirmation of Huntington Disease (HD) gene expansion mutation carrier status - Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) \>6 within 12 months prior to signing the ICF - Ability to tolerate blood draws Who Should NOT Join This Trial: - None Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Have signed the Informed Consent Form (ICF) * Aged 25 to 60 years, inclusive, at the time of signing the ICF * Confirmation of Huntington Disease (HD) gene expansion mutation carrier status * Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) \>6 within 12 months prior to signing the ICF * Ability to tolerate blood draws Exclusion Criteria: * None

Locations (20)

Uab Medicine
Birmingham, Alabama, United States
Barrow Neurological Institute
Phoenix, Arizona, United States
University of California San Diego
La Jolla, California, United States
University of California Davis Medical System
Sacramento, California, United States
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado, United States
University of South Florida
Tampa, Florida, United States
Northwestern University
Chicago, Illinois, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
John Hopkins University School of Medicine
Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
EvergreenHealth Investigational Drug Services
Kirkland, Washington, United States
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
Calvary Health Care Bethlehem
Caulfield South, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Graylands Hospital
Mount Claremont, Western Australia, Australia
University of Alberta
Edmonton, Alberta, Canada
University of British Columbia Hospital
Vancouver, British Columbia, Canada